Eurofins cuts 2026 organic growth outlook and Eurofins stock trades at EUR 82.78

Published on 10/23/2026 at 09:57 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Nine-month revenue reached EUR 5.61 billion, up 3.70 percent year over year. Eurofins stock trades at EUR 82.78 on October 23, 2026.

Growth outlook and margin plans

Eurofins updated its 2026 organic growth objective on October 21, 2026, after reporting EUR 5.61 billion in nine-month revenue.
Eurofins kept its adjusted EBITDA margin objective at 24.00 percent for fiscal year 2027.
Eurofins stock trades at EUR 82.78 at 9:45 a.m. CEST at Lang & Schwarz on October 23, 2026.

Geometrisches Bauhaus-Poster mit Formen und Schriftzügen LAB und TESTING in Primärfarben — Bauhaus-Poster mit Schriftzügen LAB und TESTING illustriert die Branche von Eurofins Scientific SE, ISIN FR0014000MR3, Illustration mit AI erstellt.

Eurofins stock trades at EUR 82.78 at Lang & Schwarz on October 23, 2026, at 9:45 a.m. CEST. The company updated its 2026 organic growth objective after reporting EUR 5.61 billion in revenue for the first nine months, up 3.70 percent from the same period of 2025, according to MarketScreener.

Why growth guidance changed

Eurofins said on October 21, 2026, that full-year 2026 organic growth would fall below its previous mid-single-digit objective. Slower market conditions and clinical programs that are not expected to restart in 2026 weighed on the revised view, while revenue from acquisitions is expected to exceed the previous EUR 250 million annualized objective.

The quarterly progression offers a more constructive counterpoint. Organic growth increased from 2.50 percent in the first quarter of 2026 to 3.00 percent in the second quarter and 3.50 percent in the third quarter, while third-quarter revenue rose 6.10 percent year over year to EUR 1.91 billion, according to Investing.com.

What does the margin target mean?

Management kept its profitability and cash-flow objectives for 2026 and retained a 24.00 percent adjusted EBITDA margin objective for fiscal year 2027. The comparison point is the 22.50 percent adjusted EBITDA margin reported for fiscal year 2025, so the stated objective implies a 1.50 percentage-point increase from that historical level.

Three dated steps in the story

On July 20, 2026, Eurofins agreed to acquire Element Materials Technology's North American Life Sciences Testing Services business for an enterprise value of USD 400 million, as stated on the company's investor-relations page. On July 23, 2026, Eurofins reported 130 basis points of adjusted EBITDA margin expansion in its first-half results. On October 21, 2026, the nine-month update delivered EUR 5.61 billion in revenue and revised the 2026 organic growth objective, according to Eurofins and MarketScreener.

Dates for investors

Eurofins scheduled an investor event in Amersfoort, Netherlands, for October 23, 2026. A second investor event is scheduled for November 11, 2026, in Toronto, Canada, according to the company's investor-relations page.

Analyst expectations remain a counterweight to the operational improvement. Deutsche Bank maintained a Hold recommendation and raised its target from EUR 64.00 to EUR 67.00 on October 22, 2026, according to Zonebourse. The target remains below the Lang & Schwarz price, placing the revised growth view alongside a market valuation that already reflects part of the margin story.

Stock price and next signal

Eurofins is listed on Euronext Paris and operates across analytical testing, life sciences, diagnostics, and consumer and technology products testing. For investors, the October 23 event provides the next near-term setting for management commentary on the balance between slower organic growth and the 2027 margin objective. The stock was trading at EUR 82.78 at Lang & Schwarz on October 23, 2026, at 9:45 a.m. CEST.

The further course of trading is shown by the continuously updated real-time quote of Eurofins stock.